447 related articles for article (PubMed ID: 21887677)
21. Hybrid simultaneous whole-body 2-[
Jamet B; Carlier T; Bailly C; Bodet-Milin C; Monnet A; Frampas E; Touzeau C; Moreau P; Kraeber-Bodere F
Eur Radiol; 2023 Sep; 33(9):6438-6447. PubMed ID: 37022439
[TBL] [Abstract][Full Text] [Related]
22. Multi-parametric whole-body MRI evaluation discerns vital from non-vital multiple myeloma lesions as validated by
Heidemeier A; Schloetelburg W; Thurner A; Metz C; Heidemeier H; Rasche L; Martin Kortuem K; Boeckle D; Weiland E; Benkert T; Nickel D; Werner R; Buck AK; Bley TA
Eur J Radiol; 2022 Oct; 155():110493. PubMed ID: 36027759
[TBL] [Abstract][Full Text] [Related]
23. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
24. Comparative Performance of Whole-Body MRI and FDG PET/CT in Evaluation of Multiple Myeloma Treatment Response: Systematic Review and Meta-Analysis.
Rama S; Suh CH; Kim KW; Durieux JC; Ramaiya NH; Tirumani SH
AJR Am J Roentgenol; 2022 Apr; 218(4):602-613. PubMed ID: 34704461
[No Abstract] [Full Text] [Related]
25. 11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement.
Lapa C; Knop S; Schreder M; Rudelius M; Knott M; Jörg G; Samnick S; Herrmann K; Buck AK; Einsele H; Lückerath K
Theranostics; 2016; 6(2):254-61. PubMed ID: 26877783
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic value of WB-DWI versus
Zhang B; Zhang L; Bian B; Lin F; Zhu Z; Wang J
Indian J Cancer; 2023; 60(3):303-309. PubMed ID: 37787189
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic performance of
Basha MAA; Hamed MAG; Refaat R; AlAzzazy MZ; Bessar MA; Mohamed EM; Ahmed AF; Tantawy HF; Altaher KM; Obaya AA; Afifi AHM
Jpn J Radiol; 2018 Jun; 36(6):382-393. PubMed ID: 29671193
[TBL] [Abstract][Full Text] [Related]
28. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).
Nanni C; Zamagni E; Versari A; Chauvie S; Bianchi A; Rensi M; Bellò M; Rambaldi I; Gallamini A; Patriarca F; Gay F; Gamberi B; Cavo M; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):414-21. PubMed ID: 26475305
[TBL] [Abstract][Full Text] [Related]
29. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.
Nanni C; Zamagni E; Cavo M; Rubello D; Tacchetti P; Pettinato C; Farsad M; Castellucci P; Ambrosini V; Montini GC; Al-Nahhas A; Franchi R; Fanti S
World J Surg Oncol; 2007 Jun; 5():68. PubMed ID: 17584499
[TBL] [Abstract][Full Text] [Related]
30. 18F-FDG PET increases visibility of bone lesions in relapsed multiple myeloma: is this hypoxia-driven?
de Waal EG; Slart RH; Leene MJ; Kluin PM; Vellenga E
Clin Nucl Med; 2015 Apr; 40(4):291-6. PubMed ID: 25546223
[TBL] [Abstract][Full Text] [Related]
31. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
32. [The value of fluorodeoxyglucose positron emission tomography in multiple myeloma].
Adam Z; Bolcák K; Stanícek J; Pour L; Hájek R; Krejcí M; Prásek J; Neubauer J; Mareschova Y; Vorlícek J
Vnitr Lek; 2006 Mar; 52(3):207-14. PubMed ID: 16722151
[TBL] [Abstract][Full Text] [Related]
33. Value of FDG PET in the assessment of patients with multiple myeloma.
Bredella MA; Steinbach L; Caputo G; Segall G; Hawkins R
AJR Am J Roentgenol; 2005 Apr; 184(4):1199-204. PubMed ID: 15788594
[TBL] [Abstract][Full Text] [Related]
34. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.
Fonti R; Larobina M; Del Vecchio S; De Luca S; Fabbricini R; Catalano L; Pane F; Salvatore M; Pace L
J Nucl Med; 2012 Dec; 53(12):1829-35. PubMed ID: 23071351
[TBL] [Abstract][Full Text] [Related]
35. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
36. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.
Bartel TB; Haessler J; Brown TL; Shaughnessy JD; van Rhee F; Anaissie E; Alpe T; Angtuaco E; Walker R; Epstein J; Crowley J; Barlogie B
Blood; 2009 Sep; 114(10):2068-76. PubMed ID: 19443657
[TBL] [Abstract][Full Text] [Related]
37.
Morales-Lozano MI; Rodriguez-Otero P; Sancho L; Nuñez-Cordoba JM; Prieto E; Marcos-Jubilar M; Rosales JJ; Alfonso A; Guillen EF; San-Miguel J; Garcia-Velloso MJ
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077292
[TBL] [Abstract][Full Text] [Related]
38. 11C-acetate PET/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET/CT.
Ho CL; Chen S; Leung YL; Cheng T; Wong KN; Cheung SK; Liang R; Chim CS
J Nucl Med; 2014 May; 55(5):749-52. PubMed ID: 24676754
[TBL] [Abstract][Full Text] [Related]
39. Treatment response evaluation with
Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
[TBL] [Abstract][Full Text] [Related]
40. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer.
Qu X; Huang X; Yan W; Wu L; Dai K
Eur J Radiol; 2012 May; 81(5):1007-15. PubMed ID: 21354739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
